US 11583540
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
granted A61KA61K31/5685A61K45/06
Quick answer
US patent 11583540 (Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)) held by Windtree Therapeutics, Inc. expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Windtree Therapeutics, Inc.
- Grant date
- Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/5685, A61K45/06, A61K9/009, A61P